reported. Hereditary spastic paraplegia are classified as pure or complicated forms. Cases with pure forms only present lower limb spasticity but complicated forms have additional neurological features such as cerebellar ataxia, intellectual disabilities, dementia, thin corpus callosum, and/or visual dysfunction.
To date, over 48 spastic paraplegia loci including 20 genes have been identified. In 1994, one of these loci, SPG5A, was mapped to chromosome 8q21.3 and deemed to contain a gene underlying a pure-autosomal recessive form of HSP (MIM#270800) 1 . Many HSP families have been mapped to this particular locus and the causative gene was finally identified in 2008. Mutations in Cytochrome P450, family 7, subfamily B polypeptide 1 (CYP7B1) gene were then found to underlie this particular disorder; homozygous mutations were originally identified in a consanguineous English family 2 . CYP7B1 extends over~220 Kb gene and contain six exons that encode for an evolutionarily conserved steroid metabolizing enzyme, cytochrome P450. This particular enzyme is widely expressed in many tissues, with the highest mRNA levels found in the liver and the brain. Containing 506 amino-acid, this enzyme catalyzes the 6α-7α hydroxylation of several endogenous substrates such as: dehydroepiandrosterone, pregnenolone, oxysterols, 25-and 27-hydroxycholestrol. In the liver, CYP7B1 is implicated in the synthesis of bile salt that regulate bile flow and indirectly the excretion of metabolites (e.g. porphyrins arising from heme breakdown). Interestingly, mutations in the CYP7B1 gene are also known to cause liver failure in children. Additional roles for CYP7B1 were described in the metabolism of oestrogen receptor ligands and in immunoglobulin production 3 . The exact role of CYP7B1 in the brain is unknown, other than its link to HSP. The main goal of our study was to determine if CYP7B1 mutations could explain disease in some of our HSP patients. Genomic DNA was extracted from 30 ml blood using the Puregene DNA kit (Gentra Puregene Blood kit for 30 ml blood: RBC Lysis Solution, RNAse A Solution and Reagents); following the manufacturer's protocol (Gentra System, USA). A control cohort of 192 healthy individuals found to be free of any neurodegenerative disorder was used. PCR amplification and sequencing. UCSC ExonPrimer (http://genome.ucsc.edu/) was used to design seven sets of primers for the amplification of the six coding exons and their respective flanking splice junctions. The complete list of primers used and the PCR conditions can be found in supplementary data. Amplification products were sequenced at the Genome Quebec Innovation Centre (Montréal, Québec, Canada) using a 3730XL DNAnalyzer (Applied Biosystems, Foster City, California). Mutation surveyor (v.3.10, SoftGenetics, State College, Pennsylvania) was used for mutation detection analysis with the NM_004820 reference sequence. Mutations were confirmed by re-amplifying the fragment and sequencing its two strands (forward and reverse). Following the identification of a case showing a definite mutation, DNA from relatives was amplified, when available, to see if the mutation segregated with the disease. Mutation frequencies in cases and controls were compared using Fisher's exact test, where P<0.05 was considered statistically significant. 
METHODS

Patient
RESULTS
An overall sequencing success rate of 99.7% was obtained in our HSP cohort. The Table lists all the mutations identified in this study. We first identified a homozygous mutation (c.1450G>A) in the sixth exon of CYP7B1 that change a perfectly conserved amino-acid (p.R417H). The family of this French Canadian case ( Figure, Family A) has a recessive inheritance pattern. The unaffected mother and one unaffected brother were found to be heterozygote carriers for the c.1450G>A mutation; DNA from other family members was not available. The proband had definite HSP with disease onset at the age of seven, and some sensory involvement and seizures. A homozygous c.1450G>A mutation was previously reported in a Tunisian consanguineous family 2 and as a compound heterozygous state in a French sporadic case 4 . The second case was an unrelated French Canadian family (Figure, Family B) , both the HSP proband and her affected brother had compound heterozygous mutations in CYP7B1. The proband was seen by a neurologist who made the diagnosis of HSP or spastic-ataxia with marked sensory involvement. Disease onset was at 22 years-of-age, but brisk tendons reflexes had been previously observed. Both the proband and her brother had an allele with a c.825T>A change that translates to a protein truncating nonsense mutation (p.Y275X). Homozygous c.825T>A mutations were previously reported in a Portuguese sporadic HSP case in whom additional features of optic atrophy were noted 4 . The second mutated allele of CYP7B1 was found to be a c.1456C>T change that creates a missense mutation p.R486C in the last exon. This c.1456C>T mutation was reported in a consanguineous Portuguese family 4 . None of the parents or the three other unaffected siblings were available for gene screening.
The third case (Figure, Family C) was again from a French Canadian family with a diagnosis of HSP associated with a mild sensory deficit. The age of onset was as early as four years old and no other family member was affected, though one uncle and one aunt, on her mother's side, had severe multiple sclerosis. The screening of CYP7B1 revealed compound heterozygous mutations. One of the mutated alleles had the p.Y275X mutation described in family B, and the other a missense mutation c.889A>G in the fourth exon that produce a p.T297A amino-acid change, that was already described by Goizet et al 4 . The mother was tested for mutations in CYP7B1 and found to carry only the truncating mutation. None of these two mutations were observed in the unaffected brother, thus confirming the segregation of mutations for the disease. Unfortunately, the father was not available for mutation detection analysis.
DISCUSSION
We report here another CYP7B1 heterozygote mutation, c.971G>A (p.R324H), in five families with recessive inheritance and four families with dominant inheritance. This variant was listed in dbSNP (rs59035258) and has an average heterozygosity of 2.8%. A comparative analysis of its mutation frequencies in our 86 HSP cases and 178 control individuals indicated these were respectively 9.30% and 5.06%; a non-significant difference when using a Fisher test (p-value = 0.2882; OR = 1.83). Moreover, additional family members were screened, when available, and there was no segregation of this variant with the disease. This mutation was considered by Schüle et al as a phenotype modifier of complex HSP phenotypes 5 ; we have no data to support this contention.
All the mutations identified in this study were previously reported in SPG5A families, though not in the same compound heterozygous combinations. Our results suggest that mutation in CYP7B1 may be responsible for 9.1% of the autosomal recessive cases of HSP. This mutation frequency is similar to the 10.8% of autosomal recessive families reported in a meta-analysis by Arnoldi et al 6 . We can also say that the phenotypes observed were similar to HSP subjects already described. It is interesting to note that our three patients harbouring mutations in CYP7B1 had reduced sensation in their lower extremities. This sign was also found in familial cases described by Arnoldi et al. 6 One of our 33 seemingly sporadic cases has a CYP7B1 mutation, suggesting that it may be worthwhile screening this gene in such cases, especially if they have prominent sensory signs and symptoms. For clinicians following French-Canadian HSP patients, it may be pertinent to request a mutational screening analysis of CYP7B1 as the number of mutations identified in patients from this population is substantial. The number of French-Canadian HSP cases investigated may be too small for a clearly significant prevalence of SPG5 cases to be observed. For now, the easiest and cheapest way to proceed is by Sanger sequencing. In the near future, it will be possible to use diagnostic tools that will be developed, to do screening of all the genes involved in HSP. This will ensure a rapid clinical diagnosis and will hopefully help to treat patients according to the causative gene involved.
